Researchers Identify Biomarkers for Obesity Risk in Women

Low levels of a biochemical process involved in fat breakdown predicts weight gain and metabolic complications more than a decade later.

Written byCatherine Offord
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

ISTOCK, STOCKVISUALAn impaired ability to break down fats is associated with later weight gain and metabolic disorders in women, according to a study published today (May 31) in Cell Metabolism. Researchers at the Karolinska Institute found that low levels of a biochemical process known as hormone-stimulated lipolysis were linked to increased weight and complications such as type 2 diabetes 13 years later, offering the possibility of a diagnostic test for obesity risk as well as improved interventions.

“This information could be used by clinicians to determine who would benefit the most from intensified lifestyle interventions such as physical activity, which enhances hormone-stimulated lipolysis and may therefore prevent fat accumulation and metabolic disturbances,” study coauthor Mikael Ryden says in a statement.

Ryden and his colleagues collected fat biopsies from 89 women, and followed up after an average of 13 years. The team found that, compared with women who went on to maintain a stable weight over that period, women who gained weight over the course of the study showed relatively low levels of hormone-stimulated lipolysis and low expression of genes involved in regulating fat breakdown.

The researchers also developed an algorithm to estimate the rates of hormone-stimulated lipolysis on the basis of biomarkers ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • After undergraduate research with spiders at the University of Oxford and graduate research with ants at Princeton University, Catherine left arthropods and academia to become a science journalist. She has worked in various guises at The Scientist since 2016. As Senior Editor, she wrote articles for the online and print publications, and edited the magazine’s Notebook, Careers, and Bio Business sections. She reports on subjects ranging from cellular and molecular biology to research misconduct and science policy. Find more of her work at her website.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies